Dabrafenib

Chemical formula: C₂₃H₂₀F₃N₅O₂S₂  Molecular mass: 519.562 g/mol  PubChem compound: 44462760

Therapeutic indications

Dabrafenib is indicated for:

Melanoma with a BRAF V600 mutation

Population group: only adults (18 years old or older)

Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Non-small cell lung cancer (NSCLC) with a BRAF V600 mutation

Population group: only adults (18 years old or older)

Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Stage III melanoma with a BRAF V600 mutation

Population group: only adults (18 years old or older)

Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Low-grade glioma with a BRAF V600E mutation

Population group: only children (1 year - 12 years old)

Dabrafenib in combination with trametinib is indicated for the treatment of paediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

High-grade glioma with a BRAF V600E mutation

Population group: only children (1 year - 12 years old)

Dabrafenib in combination with trametinib is indicated for the treatment of paediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.